Price
$869.58+9.68%Social Signal Score
Analyst Ratings
31 analystsRevenue
$105.38B+110.94%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian S. Tyler
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Employees
- 42,300
- Beta
- 0.31
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 5.85
Financials
Revenue
$105.38B+110.9%Net Income
$614.00M+99.4%EBITDA
$1.39B+68.9%Free Cash Flow
$-332.00M-135.2%EPS (diluted)
$5.15+284.3%Shares Outstanding (diluted)
119.20M-47.7%Operating Expenses
$2.26BCash & Debt
$5.16BReturn of Capital
$2.63BRevenue by Segment (annual)
$403.43BDividend per Share
$0.94Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $403.43B | $4.76B | $38.55 |
| 2025 | $359.05B | $3.29B | $25.86 |
| 2024 | $308.95B | $3.00B | $22.54 |
| 2023 | $276.71B | $3.56B | $25.23 |
| 2022 | $263.97B | $1.11B | $7.31 |
| 2021 | $238.23B | $-4.54B | $-27.02 |
| 2020 | $231.05B | $900.00M | $4.97 |
| 2019 | $214.32B | $34.00M | $0.17 |
| 2018 | $208.36B | $67.00M | $0.32 |
| 2017 | $198.53B | $5.18B | $22.95 |
| 2016 | $190.88B | $2.26B | $9.82 |
| 2015 | $179.04B | $1.48B | $6.37 |
| 2014 | $137.61B | $1.26B | $5.51 |
| 2013 | $122.45B | $1.34B | $5.71 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MCK's reported EPS growth of 15.8% a year over 13 years.
- EPS in 5 years
- $80.23
- Implied price
- $1,765
- Return from $902.28
- 14.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $877.50 — -2.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| 5.8% | -2.0% | 1.5% | 4.5% | 7.2% | 9.6% |
| 10.8% | 2.7% | 6.3% | 9.4% | 12.3% | 14.8% |
| 15.8% | 7.3% | 11.1% | 14.4% | 17.3% | 20.0% |
| 20.8% | 11.9% | 15.9% | 19.3% | 22.4% | 25.2% |
| 25.8% | 16.6% | 20.6% | 24.2% | 27.5% | 30.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
97+9.43%Social Signal Score
Mentions (36)
- News (RSS)seekingalpha·12h ago·Neutral
McKesson, CD&R in talks for $5B deal for Option Care Health: FT
View source ↗ - News (RSS)ft·13h ago·Positive
McKesson and CD&R near $5bn-plus deal to buy infusion services provider Acquisition of Option Care Health would be the latest buyout of an undervalued healthcare services company
View source ↗ - Newsfool.com·4d ago·Negative
Why McKesson Stock Soared More Than 5% Higher Today The arrangement is now in force through June 2032. McKesson also reaffirmed its guidance for the current fiscal year.
View source ↗ - Newsbusinesswire.com·5d ago·Positive
McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies, and distribution centers through June 2032. “We are pleased to extend our long-standing, strategic relationship with CVS Health and continue supporting their im…
View source ↗ - Newszacks.com·5d ago·Negative
McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know McKesson (MCK) reached $853.81 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.
View source ↗ - Newszacks.com·6d ago·Negative
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now McKesson's specialty distribution, oncology and GLP-1 growth are driving earnings, while drug pricing, margin pressure and policy uncertainty pose challenges.
View source ↗ - Newszacks.com·11d ago·Positive
Cardinal Health vs. McKesson: Which Healthcare Stock Is Better? CAH's specialty-led growth, stronger EPS outlook and improving estimate momentum set up a compelling case against MCK.
View source ↗ - Newszacks.com·12d ago·Neutral
Why McKesson (MCK) Dipped More Than Broader Market Today The latest trading day saw McKesson (MCK) settling at $880.5, representing a -1.2% change from its previous close.
View source ↗ - Newszacks.com·12d ago·Neutral
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - Newszacks.com·13d ago·Positive
Why McKesson (MCK) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·19d ago·Neutral
McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know McKesson (MCK) closed at $887.29 in the latest trading session, marking a -1.36% move from the prior day.
View source ↗ - News (RSS)yahoo·19d ago·Positive
Alluvium Raised Its McKesson (MCK) Stake as Long-Term Growth Expectations Remain Strong
View source ↗ - News (Alpha Vantage)Simply Wall Street·20d ago·Positive
Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)? McKesson (MCK) recently increased its full-year EPS guidance, expecting 13-15% growth, and announced plans to rebrand its Medical-Surgical unit as Wellverse with a potential IPO in late 2027. The company is also acquiring Precision Medicine Group to enhance its oncology and biopharma services. While these developments signal operational strength and strategic expansion, the core investment narrative, including risks like dru…
View source ↗ - Newsseekingalpha.com·21d ago·Positive
McKesson Corporation (MCK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript McKesson Corporation (MCK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·22d ago·Positive
McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal McKesson NYSE: MCK executives said the company's first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions businesses.
View source ↗ - Newszacks.com·25d ago·Neutral
McKesson (MCK) Suffers a Larger Drop Than the General Market: Key Insights McKesson (MCK) closed at $880.86 in the latest trading session, marking a -1.21% move from the prior day.
View source ↗ - Newszacks.com·26d ago·Neutral
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - News (RSS)seekingalpha·27d ago·Positive
McKesson Corporation (MCK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·27d ago·Positive
McKesson Corporation (MCK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript McKesson Corporation (MCK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·28d ago·Neutral
McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates McKesson NYSE: MCK discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter.
View source ↗ - Newsseekingalpha.com·28d ago·Positive
… increase and strategic acquisitions reinforcing the shift toward higher-margin businesses. Despite negative shareholder equity from buybacks and opioid liabilities, MCK maintains strong liquidity, low leverage, and disciplined capital returns.
View source ↗ - News (RSS)yahoo·29d ago·Positive
McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy
View source ↗ - News (RSS)yahoo·31d ago·Positive
McKesson Stock: Is MCK Outperforming the Healthcare Sector?
View source ↗ - Newszacks.com·32d ago·Positive
Here's Why McKesson (MCK) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·33d ago·Positive
Here's Why McKesson (MCK) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newstechcrunch.com·35d ago·Neutral
Hackers claim millions of patient records stolen during data breach at healthcare giant McKesson A prolific hacking group has taken credit for last week's cyberattack against U.S. pharmaceutical distribution giant McKesson, leading to the latest spill of highly sensitive health data by an American healthcare company in recent months.
View source ↗ - News (RSS)yahoo·38d ago·Neutral
McKesson Corporation (MCK) Doubles Down on Healthcare Growth With Precision Medicine Acquisition
View source ↗ - News (Marketaux)gurufocus.com·38d ago·Neutral
McKesson Corporation (MCK) Discloses Cybersecurity Incident in SEC Filing McKesson Corporation M[+291 characters]
View source ↗ - News (Marketaux)gurufocus.com·38d ago·Positive
MCK Looks 8.2% Overvalued on GF Value™ On August 28, 2026, McKesson <e[+294 characters]
View source ↗ - Newszacks.com·41d ago·Negative
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.
View source ↗ - Newsreuters.com·42d ago·Negative
McKesson to buy Precision Medicine Group in about $2.25 billion deal U.S. drug distributor McKesson said on Tuesday it would buy clinical research and biopharma commercialization services provider Precision Medicine Group in a deal valued at about $2.25 billion.
View source ↗ - Newszacks.com·42d ago·Neutral
McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate McKesson raises fiscal 2027 EPS guidance as oncology, GLP-1 volumes and specialty distribution drive faster profit growth despite cash-flow pressure.
View source ↗ - Newszacks.com·42d ago·Positive
Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation? McKesson's double-digit earnings growth, specialty expansion and capital returns support the story, but a premium valuation leaves less room for error.
View source ↗ - Newszacks.com·56d ago·Positive
Here's Why McKesson (MCK) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newsmarketbeat.com·58d ago·Neutral
McKesson Q1 Earnings Call Highlights McKesson NYSE: MCK reported fiscal first-quarter 2027 results that exceeded its expectations, citing broad-based momentum across its operating businesses and prompting the healthcare services company to raise its full-year adjusted earnings outlook.
View source ↗ - Newsseekingalpha.com·59d ago·Positive
McKesson: Solid Q1 Earnings And Management Execution (Rating Upgrade) McKesson delivered strong Q1 results, with EPS up 20% and revenues rising 7.7% while modestly raising FY27 EPS guidance. I see GLP-1-driven momentum decelerating alongside a broader dip in the company's top-line growth profile. The Wellverse spin-off and prior divestitures are streamlining MCK, potentially justifying a premium multiple versus peers.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $10.71 per share
Typical surprise +1.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$9.93 vs $9.56beat
- Thu, May 7$11.69 vs $11.56beat
- Wed, Feb 4$9.34 vs $9.17beat
- Wed, Nov 5$9.86 vs $9.03beat
- Wed, Aug 6$8.26 vs $8.14beat
- Thu, May 8$10.12 vs $9.83beat
Estimates and results for MCK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MCK officers and directors.
- Bought
- —
- Sold
- $24.0m
0 trades
11 trades
- Rutledge Napoleon B Jrsold
- Lerman Bradley Esold
- Tyler Brian S.sold
- Tyler Brian S.sold
- Tyler Brian S.sold
- Rutledge Napoleon B Jrsold
- Rodgers Thomas Lsold
- Rodgers Thomas Lsold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Sep 7, 2026 (28d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Jonathan Jacksonhouse · IL01 · disclosed Jul 16, 2026 (31d later)Sell$1,001 - $15,000
- Richard Ray Larsenhouse · WA02 · disclosed Jul 13, 2026 (5d later)Buy$1,001 - $15,000
- Ritchie Torreshouse · NY15 · disclosed Jul 9, 2026 (548d later)Buy$1,001 - $15,000
- Elizabeth Pannill Fletcherhouse · disclosed May 1, 2026 (23d later)Sell$1,001 - $15,000
- Markwayne Mullinsenate · OK · disclosed Mar 2, 2026 (26d later)Buy$15,001 - $50,000
- Markwayne Mullinsenate · OK · disclosed Feb 4, 2026 (30d later)Buy$15,001 - $50,000
- Markwayne Mullinsenate · OK · disclosed Feb 4, 2026 (30d later)Buy$15,001 - $50,000
- Jared Moskowitzhouse · FL23 · disclosed Jan 19, 2026 (48d later)Buy$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed Jan 19, 2026 (48d later)Buy$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (391d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 12, 2026 (24d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2025 (27d later)Buy$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed Nov 24, 2025 (45d later)Buy$1,001 - $15,000
- Jonathan Jacksonhouse · IL01 · disclosed Nov 11, 2025 (34d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (17d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (30d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Sep 12, 2025 (38d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.